About: Trastuzumab v liečbe karcinómu prsníka: mechanizmy účinku a rezistencie

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Trastuzumab v liečbe karcinómu prsníka: mechanizmy účinku a rezistencie Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
Description	Trastuzumab, humanizovaná monoklonálna protilátka proti HER-2 receptoru, bol prvou cielenou liečbou pre pacientky s HER-2 pozitívnym karcinómom prsnika. Samostatne, ale hlavne v kombinácii s chemoterapiou trastuzumab zvyšuje liečebnú odpoveď, predlžuje čas do progresie/relapsu ochorenia i celkové prežitie pacientok. Na strane druhej, i napriek tomu, že je trastuzumab podávaný úzkej vyselektovanej skupine pacientok, odpoveď na túto cielenú liečbu je variabilná, a to ako v rozsahu, tak i v dĺžke trvania. Príčinou je existencia primárnej a prípadne vznik sekundárnej rezistencie ochorenia voči tejto protilátke. Predpokladá sa existencia niekoľkých možných mechanizmov rezistencie a vyvíjajú sa stratégie na ich prekonanie. S tým úzko súvisia mechanizmy posobenia trastuzumabu na nádorovú bunku a možnosti predikcie odpovedi na túto liečbu.V článku ďalej poukážeme na aktuálne možnosti prekonania primárnej a indukovanej rezistencie k trastuzumabu. Trastuzumab, a humanized monoclonal antibody against the HER-2 receptor, was the first targeted therapy for HER-2 positive breast cancer. The treatment of HER-2 positive breast cancer in monotherapy, but mainly in combination with cytostatics trastuzumab, showed significant efficacy and increased the time to progression/relapse and overall survival. On the other hand, despite it being administered to only a selected patient population, the response rate varies in range and duration due to the primary or acquired tumor resistance to trastuzumab. Several mechanisms contributing to the drug resistance are presumed and overcoming strategies are in development. In connection with the drug resistance there are the mechanisms of trastuzumab's action on tumor cells and the search for feasible biomarkers in order to predict the response of trastuzumab-based targeted therapies. Furthermore, we present here the actual possibilities to overcome primary or acquired trastuzumab resistance. (en)
Title	Trastuzumab v liečbe karcinómu prsníka: mechanizmy účinku a rezistencie Trastuzumab in the breast cancer treatment: efficacy and resistance mechanisms (en)
skos:prefLabel	Trastuzumab v liečbe karcinómu prsníka: mechanizmy účinku a rezistencie Trastuzumab in the breast cancer treatment: efficacy and resistance mechanisms (en)
skos:notation	RIV/00209805:_____/09:#0000109!RIV10-MZ0-00209805
http://linked.open...avai/riv/aktivita	P
http://linked.open...avai/riv/aktivity	P(NR8335)
http://linked.open...iv/cisloPeriodika	2
http://linked.open...vai/riv/dodaniDat	2010
http://linked.open...aciTvurceVysledku	Grell, Peter Šimíčková, Marta Vyzula, Rostislav Svoboda, Marek Fabian, Pavel
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Masarykův onkologický ústav
http://linked.open...dnocenehoVysledku	346846
http://linked.open...ai/riv/idVysledku	RIV/00209805:_____/09:#0000109
http://linked.open...riv/jazykVysledku	sla - slovenština
http://linked.open.../riv/klicovaSlova	Trastuzumab, breast cancer, oncogene protein HER-2, mechanism of action, drug resistance (en)
http://linked.open.../riv/klicoveSlovo	drug resistance mechanism of action breast cancer oncogene protein HER-2 Trastuzumab
http://linked.open...odStatuVydavatele	CZ - Česká republika
http://linked.open...ontrolniKodProRIV	[4FC1B7BC1202]
http://linked.open...i/riv/nazevZdroje	Klinická onkologie
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	5 (xsd:int)
http://linked.open...cetTvurcuVysledku	5 (xsd:int)
http://linked.open...vavai/riv/projekt	Prediction of chemosensitivity / chemoresistance to the target therapy of breast carcinoma with amplification of the Her-2 gene, based on the analysis of Akt signal pathway and serial quantitative testing for serum HER-2/neu extracellular domain
http://linked.open...UplatneniVysledku	2009
http://linked.open...v/svazekPeriodika	22
http://linked.open...iv/tvurceVysledku	Svoboda, Marek Vyzula, Rostislav Fabian, Pavel Grell, Peter Šimíčková, Marta
issn	0862-495X
number of pages	7 (xsd:int)

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 47 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software